BCL2 and diffuse large B-cell lymphoma: Nevertheless, different drugs were beneficial in different subgroups (Bcl-2 protein overexpression by immunohistochemistry, CD20+, ABC-type/non-GCB type DLBCL) in PFS, OS, or event-free survival (EFS) (17–19).